Podcast Episodes
Back to SearchSingle cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance
Season 9
In this week's episode, we’ll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune …
Published on 3 months ago
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE
Season 9
In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulin…
Published on 3 months, 1 week ago
How I Treat Transfusion Medicine (part 2)
Season 9
In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George.
Find th…
Published on 3 months, 2 weeks ago
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma
Season 9
In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodi…
Published on 3 months, 2 weeks ago
How I Treat Transfusion Medicine (part 1)
Season 9
In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive…
Published on 3 months, 3 weeks ago
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT
Season 9
In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatme…
Published on 3 months, 3 weeks ago
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease
Season 9
In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; ho…
Published on 4 months ago
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature
Season 9
In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and prog…
Published on 4 months, 1 week ago
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell cardiomyopathy
Season 9
In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematop…
Published on 4 months, 2 weeks ago
How I Treat Myeloproliferative Neoplasms
Season 9
In this How I Treat series episode Blood Associate Editor, Dr. Jason Gotlib speaks with Drs. Aaron Gerds, Andreas Reiter, and Claire Harrison. The conversation focuses on the work and contributions o…
Published on 4 months, 3 weeks ago